238 related articles for article (PubMed ID: 16735984)
41. Frequent and Rare HABP2 Variants Are Not Associated with Increased Susceptibility to Familial Nonmedullary Thyroid Carcinoma in the Spanish Population.
de Randamie R; Martos-Moreno GÁ; Lumbreras C; Chueca M; Donnay S; Luque M; Regojo RM; Mendiola M; Hardisson D; Argente J; Moreno JC
Horm Res Paediatr; 2018; 89(6):397-407. PubMed ID: 29895015
[TBL] [Abstract][Full Text] [Related]
42. Familial non-medullary thyroid cancer: a matched-case control study.
Maxwell EL; Hall FT; Freeman JL
Laryngoscope; 2004 Dec; 114(12):2182-6. PubMed ID: 15564841
[TBL] [Abstract][Full Text] [Related]
43. CHEK2 germline variants identified in familial nonmedullary thyroid cancer lead to impaired protein structure and function.
Pires C; Marques IJ; Valério M; Saramago A; Santo PE; Santos S; Silva M; Moura MM; Matos J; Pereira T; Cabrera R; Lousa D; Leite V; Bandeiras TM; Vicente JB; Cavaco BM
J Biol Chem; 2024 Mar; 300(3):105767. PubMed ID: 38367672
[TBL] [Abstract][Full Text] [Related]
44. Risk of thyroid cancer in first-degree relatives of patients with non-medullary thyroid cancer by histology type and age at diagnosis: a joint study from five Nordic countries.
Fallah M; Pukkala E; Tryggvadottir L; Olsen JH; Tretli S; Sundquist K; Hemminki K
J Med Genet; 2013 Jun; 50(6):373-82. PubMed ID: 23585692
[TBL] [Abstract][Full Text] [Related]
45. Localization of a susceptibility gene for familial nonmedullary thyroid carcinoma to chromosome 2q21.
McKay JD; Lesueur F; Jonard L; Pastore A; Williamson J; Hoffman L; Burgess J; Duffield A; Papotti M; Stark M; Sobol H; Maes B; Murat A; Kääriäinen H; Bertholon-Grégoire M; Zini M; Rossing MA; Toubert ME; Bonichon F; Cavarec M; Bernard AM; Boneu A; Leprat F; Haas O; Lasset C; Schlumberger M; Canzian F; Goldgar DE; Romeo G
Am J Hum Genet; 2001 Aug; 69(2):440-6. PubMed ID: 11438887
[TBL] [Abstract][Full Text] [Related]
46. [Familial nommedullary thyroid cancer].
Santos RB; Melo TG; Assumpção LV
Arq Bras Endocrinol Metabol; 2007 Jul; 51(5):769-73. PubMed ID: 17891240
[TBL] [Abstract][Full Text] [Related]
47. Familial Nonmedullary Thyroid Carcinoma: A Retrospective Analysis of 117 Families.
Zhang YB; Wang XX; Zhang XW; Li ZJ; Liu J; Xu ZG; Tang PZ
Chin Med J (Engl); 2018 Feb; 131(4):395-401. PubMed ID: 29451143
[TBL] [Abstract][Full Text] [Related]
48. From nodule to differentiated thyroid carcinoma: contributions of molecular analysis in 2012.
Albarel F; Conte-Devolx B; Oliver C
Ann Endocrinol (Paris); 2012 Jun; 73(3):155-64. PubMed ID: 22503804
[TBL] [Abstract][Full Text] [Related]
49. Identification of Rare Variants Predisposing to Thyroid Cancer.
Wang Y; Liyanarachchi S; Miller KE; Nieminen TT; Comiskey DF; Li W; Brock P; Symer DE; Akagi K; DeLap KE; He H; Koboldt DC; de la Chapelle A
Thyroid; 2019 Jul; 29(7):946-955. PubMed ID: 30957677
[No Abstract] [Full Text] [Related]
50. Familial non-medullary thyroid carcinoma: pathology review in 27 affected cases from 13 French families.
Leprat F; Bonichon F; Guyot M; Trouette H; Trojani M; Vergnot V; Longy M; Belleannée G; de Mascarel A; Roger P
Clin Endocrinol (Oxf); 1999 May; 50(5):589-94. PubMed ID: 10468924
[TBL] [Abstract][Full Text] [Related]
51. Familial non-medullary thyroid cancer: unraveling the genetic maze.
Peiling Yang S; Ngeow J
Endocr Relat Cancer; 2016 Dec; 23(12):R577-R595. PubMed ID: 27807061
[TBL] [Abstract][Full Text] [Related]
52. Evidence for interaction between the TCO and NMTC1 loci in familial non-medullary thyroid cancer.
McKay JD; Thompson D; Lesueur F; Stankov K; Pastore A; Watfah C; Strolz S; Riccabona G; Moncayo R; Romeo G; Goldgar DE
J Med Genet; 2004 Jun; 41(6):407-12. PubMed ID: 15173224
[TBL] [Abstract][Full Text] [Related]
53. Prevalence and prognosis of familial follicular thyroid carcinoma.
Ito Y; Fukushima M; Yabuta T; Inoue H; Uruno T; Kihara M; Higashiyama T; Takamura Y; Miya A; Kobayashi K; Matsuzuka F; Miyauchi A
Endocr J; 2008 Oct; 55(5):847-52. PubMed ID: 18506092
[TBL] [Abstract][Full Text] [Related]
54. Familial nonmedullary thyroid cancer: an emerging entity that warrants aggressive treatment.
Takami H; Ozaki O; Ito K
Arch Surg; 1996 Jun; 131(6):676. PubMed ID: 8645080
[No Abstract] [Full Text] [Related]
55. Endocrine tumours: familial nonmedullary thyroid carcinoma is a more aggressive disease: a systematic review and meta-analysis.
Wang X; Cheng W; Li J; Su A; Wei T; Liu F; Zhu J
Eur J Endocrinol; 2015 Jun; 172(6):R253-62. PubMed ID: 25637073
[TBL] [Abstract][Full Text] [Related]
56. FAMILIAL NON-MEDULLARY THYROID CARCINOMA.
Guda BB; Komisarenko II; Ostafiichuk MV; Tronko MD
Exp Oncol; 2023 Jun; 45(1):70-78. PubMed ID: 37417280
[TBL] [Abstract][Full Text] [Related]
57. The pathologist's role in familial nonmedullary thyroid tumors.
Cameselle-Teijeiro J
Int J Surg Pathol; 2010 Jun; 18(3 Suppl):194S-200S. PubMed ID: 20484290
[No Abstract] [Full Text] [Related]
58. The T1799A BRAF mutation is not a germline mutation in familial nonmedullary thyroid cancer.
Xing M
Clin Endocrinol (Oxf); 2005 Sep; 63(3):263-6. PubMed ID: 16117812
[TBL] [Abstract][Full Text] [Related]
59. Targeted DNA Sequencing Detects Mutations Related to Susceptibility among Familial Non-medullary Thyroid Cancer.
Yu Y; Dong L; Li D; Chuai S; Wu Z; Zheng X; Cheng Y; Han L; Yu J; Gao M
Sci Rep; 2015 Nov; 5():16129. PubMed ID: 26530882
[TBL] [Abstract][Full Text] [Related]
60. Hereditary and familial thyroid tumours.
Guilmette J; Nosé V
Histopathology; 2018 Jan; 72(1):70-81. PubMed ID: 29239041
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
